{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T17:57:39Z","timestamp":1725213459193},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.reuma.2013.11.010","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T11:45:39Z","timestamp":1390995939000},"page":"265-266","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elevaci\u00f3n de transaminasas secundaria a uso de adalimumab"],"prefix":"10.1016","volume":"10","author":[{"given":"Marietta Luz","family":"Juan-Guardela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisseth Fernanda","family":"Mar\u00edn-Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Ximena","family":"Kattah-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Fern\u00e1ndez-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2013.11.010_bib0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.11.010_bib0010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3109\/s10165-011-0557-x","article-title":"A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis","volume":"22","author":"Kobayashi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reuma.2013.11.010_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","article-title":"TNFalpha blockade in human diseases: An overview of efficacy and safety","volume":"126","author":"Lin","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.reuma.2013.11.010_bib0020","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":"Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis","volume":"69","author":"Sokolove","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.11.010_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5414\/CPP49038","article-title":"Subacute liver failure induced by adalimumab","volume":"49","author":"Hagel","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.reuma.2013.11.010_bib0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.autrev.2012.03.010","article-title":"Drug induced autoimmune hepatitis and TNF-\u03b1 blocking agents: Is there a real relationship?","volume":"12","author":"Efe","year":"2013","journal-title":"Autoimmunity Rev"},{"key":"10.1016\/j.reuma.2013.11.010_bib0035","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2013.11.010_bib0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","article-title":"Problems encountered during anti-tumour necrosis factor therapy","volume":"20","author":"Desai","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X1300226X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X1300226X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T21:50:47Z","timestamp":1538862647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X1300226X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1699258X1300226X"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2013.11.010","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevaci\u00f3n de transaminasas secundaria a uso de adalimumab","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2013.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}